{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000340.3:c.91G>C",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "G",
            "alt": "C",
            "position": "91"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "P",
            "position": "30"
          },
          "Description in input context": "A30P mutant shows reduced PLD2 inhibition compared to wild-type."
        },
        {
          "HGVS": "NM_000340.3:c.157G>A",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "G",
            "alt": "A",
            "position": "157"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T mutant shows increased PLD2 inhibition compared to wild-type."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005312"
  },
  "Experiment Method": [
    {
      "Assay Method": "In vitro PLD2 inhibition assay",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "Wild-type and mutant SNCA isoforms",
        "Description": "Assays involved recombinant SNCA proteins with deletions (exon 4, exon 6) and phosphorylation modifications."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.91G>C",
          "Conclusion": "Reduced inhibition",
          "Molecular Effect": "intermediate effect",
          "Result Description": "A30P mutant shows decreased PLD2 inhibition compared to wild-type."
        },
        {
          "Variant": "NM_000340.3:c.157G>A",
          "Conclusion": "Increased inhibition",
          "Molecular Effect": "gain-of-function",
          "Result Description": "A53T mutant shows enhanced PLD2 inhibition compared to wild-type."
        },
        {
          "Variant": "Deletion of exon 4",
          "Conclusion": "Reduced inhibition",
          "Molecular Effect": "partial loss-of-function",
          "Result Description": "Deletion of exon 4 (positions 100-150) reduces PLD2 inhibition by 50%."
        },
        {
          "Variant": "Deletion of exon 6",
          "Conclusion": "Abolished inhibition",
          "Molecular Effect": "loss-of-function",
          "Result Description": "Deletion of exon 6 (positions 200-250) completely abolishes PLD2 inhibition."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}